Polyrizon Launches Preclinical Trials for Intranasal Naloxone

Polyrizon Ltd. ( (PLRZ) ) has issued an announcement.

Polyrizon Ltd. announced on March 10, 2025, the initiation of preclinical studies for an intranasal Naloxone product aimed at treating opioid overdoses. This development leverages their Trap and Target™ platform, which is designed to enhance drug delivery and effectiveness. The studies, conducted with Professor Fabio Sonvico from the University of Parma, will evaluate key parameters such as drug loading capacity and release kinetics. This initiative is part of Polyrizon’s efforts to address the global opioid crisis by providing a more effective and accessible Naloxone delivery method, potentially benefiting emergency responders and at-risk individuals.

More about Polyrizon Ltd.

Polyrizon Ltd. is a development stage biotech company that specializes in the creation of innovative medical device hydrogels delivered as nasal sprays. These sprays form a hydrogel-based shield in the nasal cavity to protect against viruses and allergens. The company is advancing its Capture and Contain™ hydrogel technology and its Trap and Target™ platform for the nasal delivery of active pharmaceutical ingredients.

YTD Price Performance: -54.92%

Average Trading Volume: 3,069,156

See more insights into PLRZ stock on TipRanks’ Stock Analysis page.